Bimatoprost - CAS 155206-00-1

Quick Inquiry

* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Product Name
Catalog Number
CAS Number
Molecular Weight
Molecular Formula
Quality Standard
CAS 155206-00-1 Bimatoprost
White or off-white power
For research used only
Reference Reading
1. Bimatoprost Versus Latanoprost in Lowering Intraocular Pressure in Glaucoma and Ocular Hypertension: Results From Parallel-Group Comparison Trials
Steven T. Simmons, Monte S. Dirks, Robert J. Noecker. Advances In Therapy. Volume 21 No. 4 July/August 2004
At each of the 6 time points during which data were reported, patients given bimatoprost, compared with those given latanoprost, demonstrated a numerically lower mean IOP and a numerically greater mean IOP reduction. In the intent-to-treat patient population, the mean IOP reduction in all treatment groups at week 12 did not differ significantly (ranging from 6.5–8.7 mm Hg in the bimatoprost group, 5.9–8.6 mm Hg in the latanoprost group, and 4.7–7.9 mm Hg in the travoprost group) (Fig 1). The between-group differences at all diurnal time points also were not significant, but the differences observed at the 12 PM, 4 PM, and 8 PM time points were greater than that at the 8 AM time point. An analysis of results for the per-protocol patient population was reported only for the primary endpoint (IOP reduction at 8 AM, week 12). Bimatoprost lowered IOP significantly more effectively than travoprost (difference between groups, 0.93 mm Hg; 95% confidence interval [CI], 0.22 to 1.65). Bimatoprost was also associated with a greater mean reduction in IOP than was latanoprost, but the difference between these two treatment groups (0.23 mm Hg) was not statistically significant.
2. Efficacy of Bimatoprost in Glaucoma and Ocular Hypertension Unresponsive to Latanoprost
Robert D. Williams. Advances In Therapy. Volume 19 No. 6 November/December 2002
During phase 2 the mean IOP in bimatoprost-treated eyes was 20.1 ± 4.2 mm Hg (mean reduction from unmedicated baseline of 6.1 ± 3.8 mm Hg, P<.001) and 20.7 ± 5.1 mm Hg (mean reduction from baseline of 5.4 ± 4.8 mm Hg, P<.001) at visit 4 (Fig 2). In between-phase comparisons of IOP, bimatoprost provided statistically significant additional reductions from mean latanoprost-treated IOP. After 4 weeks of bimatoprost (visit 3), the mean IOP reduction from visit 2 was 4.2 ± 2.9 mm Hg (P<.001). After 8 weeks of bimatoprost (visit 4), the mean IOP reduction from visit 2 was 3.5 ± 3.3 mm Hg (P<.001).
3. Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness
Akira Sawada • Tetsuya Yamamoto. Jpn J Ophthalmol (2014) 58:423–428
Of these, bimatoprost is an analog of PGF2a-1-ethanolamide (prostamide F2a), derived from an endocannabinoid anandamide by COX-2. It has a dual action mechanism, which involves an increase of both pressure-independent (conventional outflow) and pressure-dependent aqueous humor outflow (uveoscleral outflow) in human eyes. Many researchers report that the ability of bimatoprost to reduce intraocular pressure (IOP) is equal to or greater than that of latanoprost. Bimatoprost reduces IOP by approximately 20.4–37.1 % of the baseline IOP in untreated eyes. There is, however, little information on the IOP-lowering profile when bimatoprost is switched from other prostaglandin analogs including latanoprost.
4. Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting
Michael Scott Kook • Susan Simonyi • Yong Ho Sohn • Chan Yun Kim • Ki Ho Park. Jpn J Ophthalmol (2015) 59:325–334
The prostamide bimatoprost 0.03 % is effective in reducing IOP and is generally well tolerated in long-term use. In comparative studies, bimatoprost 0.03 % had superior IOP-reducing effects compared with other prostaglandin analogs. A revised formulation, bimatoprost 0.01 %, was developed to maintain efficacy while improving tolerability, in particular, the incidence of ocular adverse events (AEs) such as hyperemia (which may reduce compliance and lead to treatment discontinuation). In a randomized, controlled study comparing the 2 formulations, bimatoprost 0.01 % was found to be equivalent to bimatoprost 0.03 % in reducing IOP over a 12-month treatment period, with improved tolerability (i.e., less frequent or severe conjunctival hyperemia).
2005 - BOC Sciences | All rights reserved